✦ LIBER ✦

A comparison of the pulmonary toxicity and chemotherapeutic activity of bleomycin-BAPP to bleomycin and pepleomycin

✍ Scribed by Erika Ginsburg; Theodore E. Gram; Michael A. Trush

Publisher: Springer
Year: 1984
Tongue: English
Weight: 438 KB
Volume: 12
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254601

No coin nor oath required. For personal study only.

✦ Synopsis

The pulmonary toxicity and antitumor activity of a new bleomycin analog butylamino-3-propylamino-3-propylamine (Blm-BAPP) was investigated and compared with bleomycin and pepleomycin. Blm-BAPP was significantly more pulmonary toxic than bleomycin and had no greater activity against B16 melanoma than either bleomycin or pepleomycin. Although pepleomycin was as equitoxic as bleomycin in producing pulmonary fibrosis, doses of pepleomycin greater than 5 mg/kg were more lethal than bleomycin. Not only did the three drugs function similarly in vivo, but they behaved similarly in two in vitro test systems: microsome-catalyzed drug-mediated DNA deoxyribose cleavage and binding to DNA.

📜 SIMILAR VOLUMES

Ultrastructure of pulmonary bleomycin to

Ultrastructure of pulmonary bleomycin toxicity

✍ Carlos W. M. Bedrpssian; Mario A. Luna; Bruce Mackay; Benjamin Lichtiger 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 1006 KB

Assessment of pulmonary and hematologic

Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog

✍ Robert A. Newman; Zahid H. Siddik; Elizabeth L. Travis; David Followill; Workene 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 692 KB

The antitumor efficacy as well as hematologic and pulmonary toxicity of Liblomycin, a new lipophilic analog of bleomycin, was evaluated in BDF1 mice. In comparison to bleomycin which was without any antitumor efficacy against P388 leukemia, a dose of 10 mg/kg Liblomycin administered on a daily sched

Pulmonary toxicity of the combination of

Pulmonary toxicity of the combination of bleomycin and peplomycin — an experimental study in rats

✍ Gerhard Mall; Arne Burkhardt 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 405 KB

Modulation of bleomycin-induced pulmonar

Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant amifostine

✍ Linda Nici; Anabela Santos-Moore; Charles Kuhn; Paul Calabresi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

## BACKGROUND. Bleomycin produces lung fibrosis in a wide variety of species. In humans, it can cause significant morbidity and mortality when used to treat malignancies such as lymphoma and testicular carcinoma. In rodents, it has been extensively used to study key mechanisms of lung injury and r

Long-term pulmonary toxicity of multiage

Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors

✍ Kharasch, Virginia S.; Lipsitz, Stuart; Santis, William; Hallowell, Jennifer A.; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Purpose:To assess long-term pulmonary effects of multiagent chemotherapy, we studied serial pulmonary function tests (PFTs) of 35 children with osteosarcoma up to 12 years after diagnosis. Patients and Methods: We analyzed 84 sets of PFTs from 35 patients diagnosed with osteosarcoma between 1981 an

Gemcitabine added to doxorubicin, bleomy

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease : Unacceptable acute pulmonary toxicity

✍ Jonathan W. Friedberg; Donna Neuberg; Helen Kim; Sarah Miyata; Mary McCauley; Da 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

## Abstract ## BACKGROUND Gemcitabine is an effective treatment for recurrent Hodgkin disease (HD), with relatively minimal associated toxicity. The authors conducted a trial substituting this drug for dacarbazine in the standard regimen to form ABVG (doxorubicin, bleomycin, vinblastine, gemcitabi